Pain is a diffi cult outcome to measure due to its multifaceted and subjective nature. The need for selecting proper outcome measures is high because of the increasing demand for scientifi cally valid demonstrations of treatment effi cacy. This article discusses some basic topics in the measurement of pain outcomes and addresses issues such as statistical versus clinical signifi cance, daily home data collection, appropriate length of outcome measurement packets, and the possibility of objective pain measurements. This article also reviews some of the more commonly used tools for measuring pain and pain-related disability. By selecting the proper tools and employing them correctly, we can obtain highly reliable and valid measures of pain outcomes in research and clinical care.
Introduction
Pain is a complex and subjective experience that poses a number of measurement challenges. However, in the current culture of evidence-based medicine, it is important that clinicians and researchers utilize sensitive and accurate pain outcome measures. Currently, there exists no valid and reliable method of objectively quantifying an individual's experience of pain. Therefore, we rely mainly on self-report measures to determine the impact of pain. Despite the challenges that pain measurement presents, a number of tools and approaches can be employed to collect useful pain estimates. This article discusses some important considerations in selecting and utilizing pain outcome measures for clinical and research purposes. We also review some of the commonly used pain measurement tools, provide a few additional recommendations in preparing a pain measurement procedure, and discuss the future of objective pain measurement. For a more comprehensive look at pain measurement, we refer readers to the excellent 2001 text by Turk and Melzack, Handbook of Pain Assessment [1].
Statistical Versus Clinical Signifi cance
Outcome measures provide a metric by which to gauge changes in the experience of pain; however, human interpretation is always needed to determine if a meaningful change has occurred. Generally, a treatment should demonstrate a statistically signifi cant effect and clinically signifi cant effect [2] . These two types of signifi cance are complementary and answer two different questions. One type of signifi cance cannot be inferred from the other. In a basic sense, statistical signifi cance answers the question, "Is this a real effect?" and clinical signifi cance answers the question, "Is this an important effect?"
Statistical and clinical signifi cance are oftentimes confused when one misinterprets a P value as an indicator of a treatment's strength. The P value is an extremely common parameter that is used to indicate how likely it is that the observed treatment effect occurred purely by chance, and does not truly indicate the treatment's effi cacy. If a statistical test showed drug A to be superior to drug B at reducing pain with P = 0.05, there is a 5% chance that the observed difference is not real, and would probably not be seen if the study was conducted again with new patients. At P = 0.0001, there is only a 0.01% chance that the results are erroneous, and we can be much more confident that the drug is having a true impact on the outcome. However, smaller P values say nothing about the actual strength of the effect. Many factors have a drastic impact on P values. For example, as sample size goes up, P values go down, even if the strength of the effect never changes. This phenomenon can lead very large studies (1000-2000 patients) to show signifi cant statistical results even when the changes in outcomes are very small, and meaningless to patients and clinicians.
To circumvent this problem of interpretability, readers should rely more on the effect size. For clinical trials, effect size is generally expressed in clinically relevant terms, such as the reduction of pain scores that occurs when switching from placebo to the active drug. To determine clinical signifi cance, the clinician or researcher must fi rst choose a metric (eg, percent reduction of pain), and then choose a cutoff that indicates a clinically meaningful change (eg, 30% reduction of pain).
Determining Cutoffs for Clinical Signifi cance
When deciding on a cutoff value for clinical signifi cance, we must determine the minimal amount of change in pain that would be valuable and important to patients. Many different approaches to determining this minimal important clinical difference have been proposed. A wellresearched cutoff method suggests that a 30% reduction of pain can be considered clinically signifi cant [3] . This level corresponds with a "much improved" or "very much improved" response from patients on a global impression of change, or 2 points on a 0 to 11 pain intensity numerical rating scale (these scales are discussed in more depth later in the article 
Measuring Daily Outcome Variables
If a treatment is tested on a small number of patients, then obtaining statistical signifi cance may be impossible, even if a large clinical effect is observed. One method for dealing with very small sample sizes involves running a crossover design, in which each patient receives all treatment conditions. The use of crossover designs over parallel designs (in which each patient receives one treatment condition) can reduce the required sample size by up to 90% [7] . These required sample sizes may be further reduced by collecting the outcome measure multiple times at baseline, and within each treatment condition [8] .
When daily measurements are used in patients with chronic pain, these assessments usually have to be selfreported in a natural environment. There are a number of challenges in collecting these real-world measures, such as the lack of control over measure completion and the poor control over the assessment environment and circumstances. Data collection methods, such as paper diaries or daily phone calls, are widely used but each has signifi cant drawbacks. Paper diaries are prone to backfi lling (leading to inaccurate retrospective guesses), and phone calls are work-intensive to study staff and may be disruptive to the patient. A newer approach to collecting home-based outcome measures involves the use of handheld computers. New units can be bought for under $100, and free software, such as the Experiential Sampling Program, is available for administering the measures [9] . However, these units may be hard to operate by elderly or impaired patients. Another drawback of using handheld computers is the possibility that the units will be lost, stolen, or damaged. To avoid potential data loss, it is recommended that data be frequently downloaded to the study site's computers, which may be done in person or via Internet-based transfer services. Wright [10] further discusses the important data considerations in biomedical research.
Available Tools
Because resources and time are always limited, we are forced to make decisions on which outcomes to include in our measurements. In some cases, a simple measure of pain intensity may be the most logical primary outcome variable. In other cases, a general indicator of work or social functioning may be more clinically relevant. Pain clinicians will recognize cases in which an individual is profoundly disabled by seemingly low pain intensity, and cases in which an individual maintains a productive and fulfi lling lifestyle despite reporting a high degree of pain. Some interventions may have little impact on pain intensity scores, but may benefi t mood, motivation, and functioning. Therefore, one of the most important decisions to make in testing a new treatment is determining what outcomes are most clinically relevant. We now review a few of the available pain outcome measures, which range from simple and narrowly defi ned, to large and multidimensional. Each has its proper place in measuring pain outcomes. We also refer readers to the IMMPACT recommendation on a core set of outcome measures [11] .
Unidimensional scales
In the busy clinical setting, pain measures must be simple, quick to administer, and easily understood by the patient. Unidimensional scales fi ll this role by providing fast (often one-item) measures of pain that can be administered multiple times with minimal administrative effort. One commonly used unidimensional tool is the numerical rating scale (NRS). Although variations exist, the instrument typically consists of scores from 0 to 10 (or 0-100), with the far left being described as "no pain" and the far right described as "worst pain imaginable." The NRS has the advantage of being administered verbally, thus not requiring patient mobility.
As an alternative to the NRS, a visual analogue scale (VAS) may be used. The patient marks anywhere along a 10-cm line to indicate their current pain intensity, which can be measured in millimeters to yield a 101-point scale.
